PR104 and G-CSF in Treating Patients With Solid Tumors

DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed solid tumors * Measurable or evaluable disease PATIENT CHARACTERISTICS: Inclusion criteria: * ECOG performance status 0-1 * Absolute neutrophil count ≥ 1.5 x 10\^9/L * Platelet count ≥ 100 x 10\^9/L * Hemoglobin ≥ 9 g/dL (no red blood cell transfusions allowed) * Serum bilirubin ≤ 1.5 times upper limit of normal (ULN) * PTT ≤ 1.5 times normal * Serum creatinine ≤ 1.5 times ULN * ALT or AST ≤ 2 times ULN (≤ 5 times ULN if liver metastases are present) * Not pregnant or nursing * Fertile patients must use effective contraception during and for 30 days after completion of study therapy * Able to read, understand, and provide written informed consent Exclusion criteria: * Evidence of a significant medical disorder or laboratory finding that, in the opinion of the investigator, compromises the patient's safety during study participation, including any of the following: * Uncontrolled infection or infection requiring a concomitant parenteral antibiotic * Uncontrolled diabetes * Congestive heart failure * Myocardial infarction within the past 6 months * Chronic renal disease * Coagulopathy (excluding prophylactic anticoagulation) * Known HIV positivity * Hepatitis B sAg-positive or known to be hepatitis C-positive with abnormal liver function tests PRIOR CONCURRENT THERAPY: * No more than 3 prior myelosuppressive chemotherapy regimens * Patients who have received more than 3 prior myelosuppressive regimens may be eligible, if considered to have adequate marrow, based on prior exposure to 1 of the following regimens: * Minimally myelosuppressive regimens * Limited courses of myelosuppressive regimens * More than 4 weeks since prior and no other concurrent licensed or investigational anticancer treatment (6 weeks for nitrosoureas or mitomycin C) * More than 24 hours since any prior radiotherapy and no likelihood of toxicity from this therapy * More than 4 weeks since major surgery * No prior radiotherapy to \> 20% of bone marrow * No prior high-dose chemotherapy (including either myeloablative or non-myeloablative transplantations) * Prior and concurrent androgen deprivation therapy allowed * Concurrent systemic steroids allowed, provided the patient has been on a stable dose for at least 2 weeks prior to first dose of PR-104 * No concurrent irradiation therapy (palliative or therapeutic), unless given in the absence of tumor progression